Quote · The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Where this was said
Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented
At 44:32 · chapter starts 43:00
The episode's most structurally contrarian argument arrives here: the popular claim that pharmaceutical companies ignore effective natural peptides because they can't be patented. Peter grants the kernel of truth — you can't patent a product of nature in raw form — but then systematically dismantles the larger claim. Companies routinely patent modified analogs, new salts, conjugates, delivery systems, manufacturing processes, and dosing regimens. Rapamycin, metformin, and the statins all began as natural molecules and became commercially patentable. Even BPC-157 has existing patents on its salts and production methods. More powerfully, Peter notes that if gray-market peptides truly worked as advertised, the same pharmaceutical industry currently racing to develop GLP-1 variants would be racing to develop them too. [1] — Peter Attia "You can't patent a product of nature, but companies routinely patent modified analogs, salts, delivery systems, and dosing regimens. Rapamy…" 43:45 The conspicuous absence of that race is telling. Many gray-market wellness peptides are in fact drugs that originated inside the pharmaceutical pipeline and were abandoned — not suppressed, but abandoned — due to inadequate efficacy, safety concerns, poor pharmacokinetics, or competition from better drugs. The CJC-1295 / tesamorelin comparison makes this concrete: same biology, developed simultaneously, but tesamorelin's superior data got it over the finish line while CJC-1295 was dropped. The gray market, Peter concludes, is pharma's salvage yard.
CJC-1295 and tesamorelin share the same underlying biology and were developed around the same time, but CJC-1295 was abandoned at phase 2 while tesamorelin reached full FDA approval — because the data were better.
You can't patent a product of nature, but companies routinely patent modified analogs, salts, delivery systems, and dosing regimens. Rapamycin, metformin, and the statins all started as natural molecules and became patentable. If gray-market peptides delivered on their claims, the same industry racing to develop GLP-1 variants would already be racing to develop them.
CJC-1295 is actually named after ConjuChem, the pharmaceutical company that developed and then abandoned it — a fact that illustrates how gray-market peptides often originate inside industry pipelines.
Many gray-market wellness peptides are drugs that originated inside the pharmaceutical pipeline and were abandoned due to inadequate efficacy, safety concerns, or poor pharmacokinetics.
